Erythropoietin suppresses myocardial inflammatory cytokine expression in acute myocardial infarction rats
10.3969/j.issn.2095-4344.2013.33.017
- VernacularTitle:促红细胞生成素抑制急性梗死心肌炎症因子的表达**☆
- Author:
Xinjin ZHANG
;
Fanli JIANG
;
Jianmei LI
- Publication Type:Journal Article
- From:
Chinese Journal of Tissue Engineering Research
2013;(33):6005-6012
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:Studies have shown that inflammatory cytokines may influence the prognosis after myocardial infarction, and play an important role in the process of cardiac remodeling. The non-hematopoietic effects of
erythropoietin have been confirmed:erythropoietin can reduce the inflammatory reaction through bending with
the erythropoietin on the surface of target cel membrane, thus decreasing the reperfusion injury after myocardial ischemia.
OBJECTIVE:To observe the effect of recombinant human erythropoietin on the inflammatory factor expression during cardiac remodeling in rats with acute myocardial infarction.
METHODS: Sprague Dawley rat models of acute myocardial infarction were established through the ligation of the left anterior descending coronary artery. The rats were divided into five groups:sham operation group was
injected with normal saline;operation control group was injected with normal saline after modeling;SB203580 group was injected with highly selective p38 MAPK inhibitor SB203580 after modeling;erythropoietin group was injected with
erythropoietin after modeling;the erythropoietin+SB203580 group was injected with erythropoietin+SB203580 mixed solution after modeling. The tail vein blood samples were col ected before modeling, 1 day, 1 week, 2 weeks and 4 weeks after modeling, and then enzyme-linked immunosorbent assay was used to detect the levels of interleukin-1β, interlrukin-6 and tumor necrosis factor-α.
RESULTS AND CONCLUSION:There were no significant differences in the levels of interleukin-1β, interlrukin-6 and
tumor necrosis factor-αbetween groups before modeling (P>0.05). There were no significant differences in the levels of interleukin-1β, interlrukin-6 and tumor necrosis factor-αbetween different time points in the sham operation group (P>0.05), and the levels were highest at 1 day after modeling in the other four groups, and then decreased at 4 weeks after modeling (P<0.05). After modeling, the level of serum cytokines in the operation control group were higher than those in the other four groups, while level of serum cytokines in the sham operation group was lower than that in the other four groups (P<0.05);among the three groups intervened with drugs, level of serum cytokines was lower in the
erythropoietin+SB203580 group (P<0.05), while there was no significant difference in the level of serum cytokines between erythropoietin group and SB203580 group (P>0.05). Recombinant human erythropoietin can inhibit the expressions of inflammatory factors (interleukin-1β, interlrukin-6 and the tumor necrosis factor-α) during cardiac
remodeling after rat acute myocardial infarction, and the mechanism of recombinant human erythropoietin for inhibiting the expressions of inflammatory factors may related with the transforming growth factorβ1-TAK1-p38 MAPK signal pathway.
